Lamivudine |
Lamivudine Products |
| Data Still Lacking on Drug Tx of Chronic HBV. (Interferon or Lamivudine Therapy).(hepatitis B virus): An article from: Pediatric News Sally Koch Kubetin International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Lamivudine delays progress of chronic hepatitis B: long-term treatment.(Clinical Rounds): An article from: Family Practice News Sharon Worcester International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Limit lamivudine therapy to patients with moderate to severe hepatitis B. (Future Antivirals may be more Effective).: An article from: Family Practice News Timothy F. Kirn International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Lamivudine if ALT is elevated, hepatitis severe. (Gastroenterology: New antivirals may limit mutations).(Brief Article): An article from: Internal Medicine News Timothy F. Kirn International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Lamivudine Treats HBV in Asians.: An article from: Family Practice News Mitchel L. Zoler International Medical News Group International Medical News Group |
Sale Price: $5.95
|
| Panel backs adefovir for chronic hepatitis B. (Benefit Seen in Lamivudine Resistance).: An article from: Internal Medicine News Elizabeth Mechcatie International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Lamivudine puts brakes on advanced HBV infection: vaccine therapy may be useful adjunct: disease progression cut by two-thirds.(News): An article from: Internal Medicine News Sharon Worcester International Medical News Group The Gale Group International Medical News Group |
Sale Price: $5.95
|
| Hepsera reduces lamivudine-resistant HBV levels in liver transplant patients.(hepatitis B): An article from: Transplant News Transplant Communications, Inc. Transplant Communications, Inc. |
Sale Price: $5.95
|
| Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B.(Case Report): An article from: Southern Medical Journal Kendal Yalcin, Halil Degertekin, Mithat Bozdayi Southern Medical Association Southern Medical Association |
Sale Price: $5.95
|

Not Signed In - 


